

Author Correction: Experimental study on thioredoxin redox inhibitor 1-methylpropyl 2-imidazolyl disulfide promoting apoptosis of multiple myeloma cells *in vitro* and *in vivo*

Q.-D. LIN, L.-N. LIU, X.-Y. LIU, Y. YAN, B.-J. FANG, Y.-L. ZHANG, J. ZHOU, Y.-F. LI, W.-L. ZUO, Y.-P. SONG

Henan Key Lab of Experimental Hematology, Henan Institute of Hematology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China

Correction to: European Review for Medical and Pharmacological Sciences 2022; 26 (4): 1283-1292. DOI: 10.26355/eurrev_202202_28121-PMID: 35253185-published online on December 15, 2022.

After publication, the authors corrected the order of the author's affiliations as follows:

Q.-D. Lin^{1,2,3,4}, L.-N. Liu^{1,2,3,4}, X.-Y. Liu^{1,2}, Y. Yan^{1,2}, B.-J. Fang^{1,2,3,4}, Y.-L. Zhang^{1,2,3,4}, J. Zhou^{1,2,3,4}, Y.-F. Li^{1,2,3,4}, W.-L. Zuo^{1,2,3,4}, Y.-P. Song^{1,2,3,4}

¹Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou City, Henan Province, China

²Henan Cancer Hospital, Zhengzhou City, Henan Province, China

³Henan Key Lab of Experimental Hematology, Zhengzhou City, Henan Province, China

⁴Henan Institute of Hematology, Zhengzhou City, Henan Province, China

There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause.